HOME > Investors > Press Releases
2017-08-04
VM BioPharma began dosing of VM202 in Phase 3 for Non-Healing Diabetic Foot Ulcers
2017-07-31
ViroMed to strengthen its global presence with top experts
2017-07-10
2017.07(IR letter) BusinessUpdates
2017-07-07
VM202 to Begin Patient Enrollment for Diabetic/Ischemic Non-healing Foot Ulcer (NHU) Phase III Clinical Trial in US
2017-06-30
ViroMed to Present at Biotech Japan 2017 Keynote Session
1 2 3 4 5 6 7 8 9 10